Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review

References

• Chou SY, Chou CK, Kuang TM, Hsu WM. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye. 2005;19(7):784–787. doi:10.1038/sj.eye.6701663.
   PubMed Web of Science ®Google Scholar
• Patil AJ, Vajaranant TS, Edward DP. Bimatoprost a review. Expert Opin Pharmacother. 2009;10(16):2759–2768. doi:10.1517/14656560903292649.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Higa R, Sugahara M, Soga T, Wakakura M, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye. 2012;26(11):1465–1472 .doi:10.1038/eye.2012.195.
   PubMed Web of Science ®Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45–52. doi:10.1517/14740338.6.1.45.
   PubMed Web of Science ®Google Scholar
• Karslioğlu MZ, Hoşal MB, Tekeli O. Periocular changes in topical bimatoprost and latanoprost use. Turkish J Med Sci. 2015;45(4):925–930. doi:10.3906/sag-1405-23.
   PubMed Web of Science ®Google Scholar
• Vass C, Hirn C, Sycha T, Findl O, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD003167. doi:10.1002/14651858.CD003167.pub3.
   Google Scholar
• Lachaine J, Hodge WG, Steffensen I, Murray C, Barnes D, Foerster V, et al. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Can J Ophthalmol. 2008;43(1):33–41 .doi:10.3129/I07-182.
   PubMed Web of Science ®Google Scholar
• Herndon LW, Williams RD, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2003;135(5):713–715. doi:10.1016/S0002-9394(02)02146-3.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2α and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005;14(5):323–328. doi:10.1111/j.0906-6705.2005.00270.x.
   PubMed Web of Science ®Google Scholar
• Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47(4 SUPPL. 1). doi:10.1016/S0039-6257(02)00328-4.
   PubMed Web of Science ®Google Scholar
• Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol. 2004;48(6):602–612. doi:10.1007/s10384-004-0110-y.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Sugahara M, Tomita G, Noguchi K, Inoue K, et al. Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension. Clin Ophthalmol. 2012;6(1):111–116 .doi:10.2147/OPTH.S27489.
   PubMedGoogle Scholar
• Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007;32(12):1037–1043. doi:10.1080/02713680701750625.
   PubMed Web of Science ®Google Scholar
• Sibilano R. Severe darkening of a facial skin graft from lantanoprost. Arch Ophthalmol. 2007;125(10):1427–1428. doi:10.1001/archopht.125.10.1427.
   PubMedGoogle Scholar
• Wirta D, Vandenburgh AM, Weng E, Whitcup SM, Kurstjens S, Beddingfield FC 3rd. Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials. Clin Ophthalmol. 2011;5:759-65. doi:10.2147/OPTH.S17457
   Google Scholar
• Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost-induced periocular skin changes in caucasians. Ophthalmology. 2006;113(11):1961–1967. doi:10.1016/j.ophtha.2006.05.041.
   PubMed Web of Science ®Google Scholar
• Lin M, Schmutz M, Mosaed S. Latanoprost-induced skin depigmentation. J Glaucoma. 2017;26(11):e246–e248. doi:10.1097/IJG.0000000000000760.
   PubMed Web of Science ®Google Scholar
• DI Staso S, Agnifili L, Cecannecchia S, DI Gregorio A, Ciancaglini M. In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma. In Vivo. 2018 Mar-Apr;32(2):211–220. doi:10.21873/invivo.11227
   Google Scholar
• Al-Zobidi M, Khandekar R, Craven ER, Hanafi S, Edward DP. Periocular skin hyperpigmentation in children treated with prostaglandin analogues. J AAPOS. 2015 Feb;19(1):49–53. doi:10.1016/j.jaapos.2014.10.018.
   Google Scholar
• Van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F, Prins MH, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a Meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–1185 .doi:10.1016/j.ophtha.2005.01.042.
   PubMed Web of Science ®Google Scholar
• Birt CM, Buys YM, Ahmed II, Trope GE. Prostaglandin efficacy and safety study undertaken by race (The Pressure study). J Glaucoma. 2010;19(7):460–467. doi:10.1097/IJG.0b013e3181c4aeac.
   PubMed Web of Science ®Google Scholar
• Edward DP, Osmanovic S, Woodruff T, Lehrer R, Ellison R, Wiest MA. The Effects of Xalatan, Travatan and Lumigan on Periocular Skin Pigmentation. Invest. Ophthalmol. Vis. Sci. 2011;52(14):231.
   Google Scholar
• Kitahara CM, Berrington de Gonzalez A, Bouville A, Brill AB, Doody MM, Melo DR, et al. Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med. 2019;179(8):1034–1042 .doi:10.1001/jamainternmed.2019.0981.
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Covert D, Walker J. Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients. Patient Patient-Centered Outcomes Res. 2011;4(2):133–141. doi:10.2165/11539460-000000000-00000.
   Web of Science ®Google Scholar
• Chien KH, Lu DW, Chen JT. Extensive facial skin pigmentation after latanoprost treatment extensive facial skin change after latanoprost Ke-Hung et al. Cutan Ocul Toxicol. 2009;28(4):185–187. doi:10.3109/15569520903232534.
   PubMed Web of Science ®Google Scholar
• Horváth O N, Letulé V, Ruzicka T, Herzinger T, Goldscheider I, von Braunmühl T, et al. Periocular discoloration after using a prostaglandin analog for eyelash enhancement: evaluation with reflectance confocal microscopy. J Cosmet Dermatol. 2017;16(1):18–20 .doi:10.1111/jocd.12281.
   PubMed Web of Science ®Google Scholar
• Tucker MA. Melanoma Epidemiology. Hematol Oncol Clin North Am. 2009;23(3). doi:10.1016/j.hoc.2009.03.010.Melanoma.
   PubMed Web of Science ®Google Scholar
• Nordlund JJ, Collins CE, Rheins LA. Prostaglandin E2 and D2 but not MSH stimulate the proliferation of pigment cells in the pinnal epidermis of the DBA/2 mouse. J Invest Dermatol. 1986;86(4):433–437. doi:10.1111/1523-1747.ep12285717.
   PubMed Web of Science ®Google Scholar
• Imesch PD, Wallow IHL, Albert DM. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol. 1997;41(SUPPL. 2):S117–S123. doi:10.1016/S0039-6257(97)80018-5.
   PubMed Web of Science ®Google Scholar
• Estève É, Beau-Salinas F, Estève L, Lemacon J-M, Autret-Leca E, Le Louet H, et al. Mélanomes associés au latanoprost: trois cas [Melanoma during latanoprost therapy: three cases]. Ann Dermatol Venereol. 2009;136(1):60–61 .doi:10.1016/J.ANNDER.2008.09.017.
   PubMed Web of Science ®Google Scholar
• Institute, N.-N. C. National cancer institute. Surveillance, epidemiology, and end results program website. Cancer stat facts: melanoma of the skin. 2021. https://seer.cancer.gov/statfacts/html/melan.html.
   Google Scholar
• Canada, G. of. Melanoma Skin Cancer. 2021. https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/melanoma-skin-cancer.html.
   Google Scholar
• Moore DE. Drug-induced cutaneous photosensitivity. Prescrire Int. 2000;9(48):117–122. doi:10.2165/00002018-200225050-00004.
   PubMed Web of Science ®Google Scholar
• Walls AC, Han J, Li T, Qureshi AA. Host risk factors, ultraviolet index of residence, and incident malignant melanoma in situ among US women and men. Am J Epidemiol. 2013;177(9):997–1005. doi:10.1093/aje/kws335.
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee SK, Lee JH, Suh JH, Kim MS, Lee UH. A case of latanoprost-induced diffuse facial skin hyperpigmentation. J Cosmet Dermatol. 2019 Dec;18(6):1717–1720. doi: 10.1111/jocd.12920
   Google Scholar
• Wand M, Ritch R, Isbey EK, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol. 2001;119:614–615. doi:10.1007/s00210-008-0334-3.
   PubMed Web of Science ®Google Scholar
• Gronich N, Lavi I, Rennert G, Saliba W. Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid. 2020;30(2):243–250. doi:10.1089/thy.2019.0205.
   PubMed Web of Science ®Google Scholar
• Dereure O. Drug-induced skin pigmentation epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253–262. doi:10.2165/00128071-200102040-00006.
   PubMedGoogle Scholar
• Nahhas AF, Braunberger TL, Hamzavi IH. An update on drug-induced pigmentation. Am J Clin Dermatol. 2019;20(1):75–96. doi:10.1007/s40257-018-0393-2.
   PubMed Web of Science ®Google Scholar
• Giménez García RM, Carrasco Molina S. Drug-induced hyperpigmentation: review and case series. J Am Board Fam Med. 2019;32(4):628–638. doi:10.3122/jabfm.2019.04.180212.
   PubMed Web of Science ®Google Scholar
• Abdel-Malek ZA, Swope VB, Amornsiripanitch N, Nordlund JJ. In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins. Cancer Res. 1987 Jun 15;47(12):3141–6.
   Google Scholar
• Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol. 2005;123(11):1541–1546. doi:10.1001/archopht.123.11.1541.
   PubMedGoogle Scholar
• Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70(5):563–569. doi:10.1006/exer.1999.0819.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Agramonte F, Jiménez JC, Montes JR. Periorbital changes associated with topical prostaglandins analogues in a Hispanic population. P R Health Sci J. 2017;36:218–222.
   PubMed Web of Science ®Google Scholar
• Sun LL, Welch RT, Vu P. Lower eyelid melanoma during bimatoprost (Lumigan) therapy Prostaglandin. Clin Exp Ophthalmol. June 2011:213–214. doi:10.3928/15428877-20100215-90.
   PubMed Web of Science ®Google Scholar
• Tressler CS, Wiseman RL, Dombi TM, Jessen B, Huang K, Kwok KK, et al. Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature. Br J Ophthalmol. 2011;95(11):1490–1495 .doi:10.1136/bjo.2010.193987.
   PubMed Web of Science ®Google Scholar
• Marsch AJ, Lagrew J, Brooke W. Skin Pigmentation and Melanoma Risk. In Advances in Malignant Melanoma-Clinical and Research Perspectives. 2011. doi:10.5772/18681.
   Google Scholar